Radiotherapy Upregulates Programmed Death Ligand-1 through the Pathways Downstream of Epidermal Growth Factor Receptor in Glioma.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 29396299.
- Also identified by DOI 10.1016/j.ebiom.2018.01.027 and PMC identifier 5835577.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In the present study, we aimed to investigate the role of epidermal growth factor receptor (EGFR) pathway in the up-regulation of programmed death ligand-1 (PD-L1) caused by radiotherapy (RT). Tissue microarrays (TMA) consisting of glioma cancer specimens from 64 patients were used to examine the correlation between PD-L1 and EGFR levels. Furthermore, we performed in vitro experiments to assess the role of EGFR pathway in RT-upregulated PD-L1 expression using human glioma cell lines U87 and U251. Our data demonstrated that the PD-L1 expression was significantly correlated with EGFR expression in glioma specimens (χ<sup>2</sup>=5.00, P=0.025). The expressions of PD-L1 at the protein and mRNA levels were both significantly up-regulated by RT (P<0.05). The expressions of phosphorylated EGFR and janus kinase 2 (JAK2) were also induced by RT (P<0.05). Besides, inhibition of EGFR pathway could abrogate the RT-triggered PD-L1 up-regulation (P>0.05). The combination of RT with EGFR inhibitor exhibited the same effect on antitumor immune response compared with the combination of RT with PD-L1 neutralizing antibody (Ab). RT could up-regulate the PD-L1 expression through the pathways downstream of EGFR in glioma.
Medical subject headings
- B7-H1 Antigen
- ErbB Receptors
- Gene Expression Regulation, Neoplastic
- Glioma
- Up-Regulation